Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Both of these pharma companies have had troubles of late, but which one will outperform the other from here on out?

Better Buy:  AbbVie vs. Johnson & Johnson

Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.

J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children

Johnson & Johnson's $8bn Fine Gets Thrown Out, And Other News: The Good, Bad, And Ugly Of Biopharma

Johnson & Johnson (JNJ) earnings for the medical device and consumer goods company's fourth quarter of 2019 have JNJ stock down on Wednesday.
The post Johnson & Johnson Earnings: JNJ Stock Ticks Lower on Q4 Results appeared first on InvestorPlace.

Johnson & Johnson Earnings: JNJ Stock Ticks Lower on Q4 Results

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q4 2019 Results - Earnings Call Transcript

The world's largest healthcare company gave investors reasons for both enthusiasm and concern.

Johnson & Johnson's Fourth-Quarter Results Leave Wall Street With Mixed Emotions

Higher R&D spending and global expansion will support JNJ stock growth, driven by Johnson & Johnson's pharmaceutical segment.
The post Johnson & Johnson Stock Will Continue To Rally Into 2020 appeared first on InvestorPlace.

Johnson & Johnson Stock Will Continue To Rally Into 2020

Johnson & Johnson (NYSE:JNJ) released its fourth-quarter earnings on Jan. 22 before market opening.

Johnson & Johnson’s Earnings Surpass Expectations, but Revenue Falls Short

Abbott Labs

Fifth Third Bancorp

Breaking Q4 Earnings News

Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.

Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 1.08% and -0.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Q4 Earnings Beat Estimates

Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2019 results before markets opened Wednesday.

Why Johnson & Johnson Stock Is Not Reacting More Positively to Earnings

Johnson & Johnson (NYSE: JNJ) reported fourth-quarter earnings of $1.88 per share on Wednesday, which beat the analyst consensus estimate of $1.87 by 0.53%.

Johnson & Johnson Reports Mixed Q4 Earnings

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations.

J&J misses revenue estimates as blockbuster drugs disappoint

Johnson & Johnson earnings topped Q4 views while sales came in light. J&J stock edged lower.

Johnson & Johnson Earnings Mixed; JNJ Stock Falls

Johnson & Johnson’s fiscal fourth-quarter profit beat Wall Street’s expectations while the company missed slightly on revenue.

Johnson & Johnson beats Wall Street expectations on profit, misses on revenue

Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Johnson & Johnson quarterly profit jumps 32%

Shares of Johnson & Johnson JNJ, +0.07% slipped 0.1% in premarket trading Wednesday, after the consumer products and drug giant reported a fourth-quarter profit that beat expectations but revenue that came up a bit shy.

Johnson & Johnson's stock slips after profit rises above expectations, but sales comes up a bit shy

Netflix

Investors will digest earnings results from Netflix and Johnson & Johnson, and existing home sales come out Wednesday.

First FANG stock report, home sales, J&J earnings: 3 things to watch for on Wednesday

Johnson & Johnson (NYSE: JNJ) releases its next round of earnings this Wednesday, January 22.

Johnson & Johnson's Q4 Earnings Outlook

Johnson & Johnson will release its Q4 and full-year 2019 results on Wednesday, January 22, and it will likely beat the consensus earnings by $0.02, in our view. For full-year 2019, Trefis estimates that the company will report revenues of $82.1 billion, marginally higher than the 2018 figure.

Can Johnson & Johnson Beat Full Year 2019 Earnings?

Logitech

Procter & Gamble

Plexus

Texas Instruments

Q4 earnings season, the World Economic Forum in Davos and President Trump's impeachment trial all get underway beginning tomorrow.

On MLK Day, a Busy Week Expected

Intel

Netflix, Johnson & Johnson, Procter & Gamble and Intel are part of Zacks Earnings Preview

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

News for Johnson & Johnson Stock (JNJ)